Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, “Journavx has been placed on Tier 3 of the Optum Rx Premium and Select Formularies and is being further evaluated by the Optum Rx National Pharmacy & Therapeutics Committee for clinical value and safety…With the growing concern over opioid use disorder, new non-opioid alternatives such as Journavx provide additional options for treatment. ” Drugs on Tier 3 are likely to cost patients more than the pain options on Tiers 1 and 2. Shares of Vertex are down 1% to $484.46 in afternoon trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Buy Rating Driven by Outpatient Market Potential and Strategic Initiatives for Journavx
- Goldman Sachs starts Sionna Therapeutics with Early-Stage Biotech designation
- Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
- Vertex Pharmaceuticals upgraded to Buy from Hold at Erste Group
- RBC says Journavx review documents hint at focus in future chronic pain data
Questions or Comments about the article? Write to editor@tipranks.com